GMP

Intravacc Announces the Publication of a GMP Process for a Semi-Synthetic Shigella Glycoconjugate Vaccine Candidate from Institut Pasteur

Intravacc

Alzheimer's Vaccine

Araclon Biotech Advances in Its Innovative Vaccine and Diagnostic Test for Alzheimer's

Araclon Biotech

License Agreement

Confirmation That the License to Develop Oral Vaccine Delivery Platform Has Been Executed

Poolbeg Pharma PLC

Partnership

Ocugen Secures Manufacturing Partnership for US Production of COVID-19 Vaccine Candidate, COVAXIN™

Ocugen, Inc.

Genetic Vaccines

Working to Overcome Analytical Challenges Posed by Genetic Vaccines

Cynthia A. Challener, Ph.D.

Pharma's Almanac

Vaccine

Vaxxas Announces $22 Million Award from U.S. Government to Advance Vaxxas Needle-Free HD-MAP™ Vaccine Patch Technology for Pandemic Response

Vaxxas

Moderna and Samsung Biologics Announce Agreement for Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine

Samsung Biologics

Vaccines

A Look at Genetic Vaccine Development and Manufacturing

Cynthia A. Challener, Ph.D.

Pharma's Almanac

Partnership

DNA Script Partners with Moderna to Develop On-Demand Vaccines and Therapeutics for DARPA

DNA Script

Immunity

The Link Between COVID-19 and Immunity

Dr. Andrew Myers

Manufacturing

Sanofi to Invest in Vaccine Production Site in Singapore

Sanofi

Vaccine

Valneva Reports Positive Phase 1/2 Data for Its Inactivated, Adjuvanted COVID-19 Vaccine Candidate, VLA2001

Valneva SE

COVID-19 Vaccine

UBC Announces Initiative to Accelerate COVID-19 Vaccine Real-World Evidence Generation

UBC

Cover Story

Facing the Challenges of the COVID-19 Pandemic: Rentschler Biopharma

Rentschler Biopharma

COVID-19 Impacts

Q: What do you think is the greatest lesson learned from the COVID-19 pandemic, and what lasting impacts do you foresee over the next 5–10 years?

Pharma's Almanac

Vaccine

Cobra Biologics Signs Supply Agreement with AstraZeneca for Manufacture of COVID-19 Vaccine Candidate

Cobra Biologics

COVID-19 Vaccine

Russia's Sputnik V COVID-19 Vaccine Is 91% Effective

The Russian Direct Investment Fund (RDIF)

COVID-19 Vaccine

Moderna’s COVID-19 Vaccine Candidate Meets its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study

Moderna

Cancer Vaccine

Moderna Announces Clinical Updates on Personalized Cancer Vaccine Program

Moderna

Fast Track

Novavax COVID-19 Vaccine Granted Fast Track Designation by U.S. FDA

Novavax